Wize Pharma set for switch to Bitcoin mining
Wize Pharma has spun off its ophthalmology drug development activities, and will begin to mine digital currencies in another month through Cosmos.
Wize Pharma (OTCQB: WIZP), from Hod Hasharon, has reported that it has met all the preconditions for implementing the offer to purchase the shares of Australian bitcoin miner Cosmos Capital Ltd. Wize Pharma expects to complete the purchase of the shares by March 9, 2021. One of the conditions was that the level of response should be a minimum of 90% of Cosmos shareholders, and as of yesterday a response had been received (including a commitment to respond) of Cosmos shareholders, holding about 94.5% of the company s equity.
Wize Pharma s Takeover Offer for Cosmos Capital Declared Unconditional
USA - English
News provided by
Share this article
Share this article
HOD HASHARON, Israel, Feb. 16, 2021 /PRNewswire/ Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that it has declared its previously announced off-market takeover offer ( Offer ) for all of the ordinary shares in Cosmos Capital Limited, a leading digital infrastructure provider based in Sydney, Australia ( Cosmos ), free from all of the conditions set out in the Offer and, accordingly, the Offer has become unconditional. A formal notice of the unconditionality of the Offer, as required under section 650F of the Corporations Act 2001 (Australia), is attached as Annexure A below.
Wize Pharma merges with Australian Bitcoin miner Cosmos
The Israeli biopharmaceutical company will spin off its drug development activity and focus on Bitcoin mining.
Israeli clinical stage biopharmaceutical company Wize Pharma Inc. (OTCQB: WIZP) will merge with privately-held Australian digital currency infrastructure provider Cosmos Capital, in an all share deal, which will ultimately leave Cosmos s shareholders owning most of Wize s shares. Wize, which is controlled by Rimon Gold, the investment arm of serial entrepreneur Yair Goldfinger, US investor Jonathan Rubini, and its CEO Noam Danenberg, will spin off its ophthalmic disorders drug development activities.
Cosmos, which was founded 18 months ago, mainly specializes in mining Bitcoin as well as providing a digital infrastructure, which aims to act as a bridge between the growing digital currency industry and traditional capital markets. Mining Bitcoin is a process of verifying transactions in digital currencies through the
Wize Pharma and Cosmos Capital enter into Bid Implementation Agreement
USA - English
- Cosmos Capital, a digital infrastructure provider, to become publicly traded through a business combination with Wize
- The combined company is expected to have approximately US$5 million in cash and cash equivalents at closing
News provided by
Share this article
HOD HASHARON, Israel, and SYDNEY, Dec. 30, 2020 /PRNewswire/
Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and Cosmos Capital Limited, a leading digital infrastructure provider based in Sydney, Australia, today announced that they have entered into a bid implementation agreement ( BIA ), whereby Wize has agreed to make an off-market takeover offer to acquire all of the outstanding shares of Cosmos, subject to satisfaction of various closing conditions set forth in the BIA, resulting in Cosmos becoming a wholly-owned subsidiary of Wize.